Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HN

Trial Details

NCT ID
NCT05112601
Phase
PHASE2
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Biospecimen Collection
  • Computed Tomography
  • Ipilimumab
  • Magnetic Resonance Imaging
  • Nivolumab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Athens, Georgia, United States|33.96095,-83.37794
  • Augusta, Georgia, United States|33.47097,-81.97484
  • Boise, Idaho, United States|43.6135,-116.20345
  • Boise, Idaho, United States|43.6135,-116.20345

Key Eligibility Criteria

  • Patients with measurable or non-measurable (detectable) recurrent endometrial cancer
  • Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined per RECIST 1.1 criteria as at least one lesion that…
  • Non-measurable (detectable) disease in a patient is defined in this protocol per RECIST 1.1 criteria as one who does not have measurable disease bu…
  • All other lesions (or sites of disease), including small lesions (longest diameter \<10 mm or pathological lymph nodes with \>= 10 to \< 15 mm shor…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →